Arbutus Biopharma Corp (ABUS) Stock
2 of the hedge funds AlphaScala tracks reported ABUS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $1.94M.
Which hedge funds own ABUS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 405K | $1.94M | -40% |
| D.E. Shaw David Shaw | 382K | $1.83M | +167% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →ABUS price chart
Powered by TradingViewWhat does Arbutus Biopharma Corp do?
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company specializing in virology with a focus on developing novel therapeutics for infectious diseases, particularly chronic hepatitis B virus (cHBV). The company leverages its deep expertise in virology to create innovative treatments that target HBV through multiple mechanisms of action, aiming to provide functional cures for patients with unmet medical needs. Its proprietary pipeline features imdusiran (AB-729), a subcutaneously delivered RNAi therapeutic that suppresses all HBV antigens including HBsAg, currently in phase 2a clinical trials, and AB-101, an oral PD-L1 inhibitor in phase 1a/1b trials designed to reawaken HBV-specific immune responses. Arbutus Biopharma Corporation also advances its in-house Lipid Nanoparticle (LNP) delivery technology to enhance therapeutic delivery. These efforts position the company as a key player in the biotechnology sector, contributing to improved treatment options in hepatology and viral disease management. Founded in 2005 and headquartered in Warminster, Pennsylvania, Arbutus Biopharma Corporation maintains a portfolio of clinical and pre-clinical assets dedicated to addressing critical virology challenges.